Skip to content
    Real-World Studies

    Malignancy Risk in Radial Sclerosing Lesions With Atypia: 3-Year Outcomes by Histologic Subgroup

    Casanova et alBreast Cancer Research and Treatment

    Malignancy Risk in Radial Sclerosing Lesions With Atypia: 3-Year Outcomes by Histologic Subgroup
    Current clinical guidelines recommend complete surgical excision following an image-guided core needle biopsy diagnosis of a radial sclerosing lesion (RSL) with associated epithelial atypia to exclude malignancy. In an observational cohort study of 105 RSLs with associated atypia diagnosed between 2020 and 2025, researchers evaluated the cumulative incidence of malignancy stratified by atypia classification and location (involving the RSL vs. in adjacent tissue).
    Following core biopsy diagnosis, surgical excision was performed for 22 of 24 (91.7%) lesions with atypical ductal hyperplasia (ADH) involving the RSL, 17 of 35 (48.6%) with ADH in adjacent tissue, 16 of 20 (80.0%) with lobular neoplasia or other atypia involving the RSL, and 7 of 26 (26.9%) with lobular neoplasia or other atypia in adjacent tissue, with remaining lesions managed via imaging surveillance.
    The 3-year cumulative incidence of malignancy was 29.2% (95% CI: 15.1, 51.6%) for ADH involving the RSL, 8.6% (95% CI: 2.8, 24.3%) for ADH in adjacent tissue, and 2.2% (95% CI: 0.3, 14.4%) for lobular neoplasia or other atypia. The authors concluded that while lesions with ADH involving the RSL are likely to harbor malignancy, the risk is lower in other subgroups, offering evidence to support shared decision-making regarding imaging surveillance for select patients.

    Key Takeaways

    • The 3-year cumulative incidence of malignancy was 29.2% (95% CI: 15.1, 51.6%) for lesions with atypical ductal hyperplasia (ADH) involving the radial sclerosing lesion (RSL), compared with 8.6% (95% CI: 2.8, 24.3%) for lesions with ADH in adjacent tissue.
    • Lesions with lobular neoplasia or other atypia had a 3-year cumulative incidence of malignancy of 2.2% (95% CI: 0.3, 14.4%).
    Read the original sourceBreast Cancer Research and Treatment